Comparing Psychometric Properties of 6 of the 5-Level and 3-Level EQ-5D Bolt-Ons in a Large, Multinational, Longitudinal General Population Sample
Value in Health (2025)
​
​
POPUP: an observational digital study reporting general population norms for the EQ-5D-5-L and HUI-3 in 8 countries.
Archives of Public Health (2025)
​
​
Caregiving burden among caregivers of people with myasthenia gravis.
Orphanet J Rare Dis (2025)​
​​
​
A cost analysis of reductions in work productivity for MG patients and their caregivers by symptom severity.
Front Public Health (2025)
​
​
A time and motion study comparing subcutaneous pembrolizumab versus intravenous pembrolizumab in combination with chemotherapy for the treatment of metastatic non-small cell lung cancer.
Adv Ther. (2025)
​​​
​
Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis.
J Neurol Sci (2024)
​
​​
Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets.
J Neurol Sci (2024)
​
​
Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: a time and motion study.
Mult Scler Relat Disord (2024)
​​​
​
The Burden Patients with Myasthenia Gravis Experience in Terms of Breathing, Fatigue, Sleep, Mental Health, Discomfort and Usual Activities in Comparison to the General Population.
Adv Ther (2023).
​​​
​
People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies.
Adv Ther (2023)
​​
​
Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores. Muscle & Nerve (2023)
​​​
​
A dashboard for the evaluation of the effect of school closures on wellbeing of children and parents.
Archives of Public Health (2023)
​
​
Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG.
BMJ open (2023)
​​
​
An EQ-5D-Y-3L Value Set for Belgium.
PharmacoEconomics (2022)
​​
​
Exploration of the Reasons Why Health State Valuation Differs for Children Compared With Adults: A Mixed Methods Approach.
Value Health (2022)
​​
​
The Effect of Transborder Mobility on COVID-19 Incidences in Belgium. International journal of environmental research and public health,
Int J Environ Res Public Health (2022)​
​
​
A US time and motion pilot study of nebulized COPD therapy in an inpatient and a long-term care setting.
Pulm Ther (2022)
Exploring the Comparability of Face-to-Face Versus Video Conference-Based Composite Time Trade-Off Interviews: Insights from EQ-5D-Y-3L Valuation Studies in Belgium and Spain.
The Patient-Patient-Centered Outcomes Research (2022)
Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG).
BMJ Open (2021)
​
Thrombectomy is a cost-saving procedure up to 24 h after onset.
Acta Neurologica Belgica (2021)
Estimating health state utilities in hemophagocytic lymphohistiocytosis. Journal of Patient-Reported Outcomes,
J Patient Rep Outcomes (2021)
​
​
Results of a time and motion survey regarding subcutaneous versus intravenous administration of daratumumab in patients with relapsed or refractory multiple myeloma.
Clinicoecon Outcomes Res (2021)
​
Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective.
Cost Eff Resour Alloc (2020)
​
The combined impact of dependency on caregivers, disability and coping strategy on quality of life after ischemic stroke.
Health and Quality of Life Outcomes (2019)
​
The Relationship between home-time, quality of life and costs after ischemic stroke: The impact of the need for mobility aids, home and car modifications on home-time.
Disabil Rehabil (2018)
Hospital financing of ischaemic stroke: determinants of funding and usefulness of DRG subcategories based on Severity of Illness.
BMC Health Serv Res (2018)
What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients' Quality of Life?
Value Health (2018)
​
​
Measuring the costs of a pediatric vaccine administration in the UK.
Vaccine. (2018)
Modified Rankin scale as a determinant of direct medical costs after stroke.
Int journal of Stroke (2017)
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.
Support Care Cancer (2017)
​
The impact of cancer-associated thrombosis and treatment related bleedings on patients' quality of life.
Annals of Oncology (2016)
​
​
Health state utilities in non-small cell lung cancer: An international study.
Asia Pac J Clin Oncol (2016)
​
​
Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries.
PLoS One (2016)
​
A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
Cancer Med (2016)
​
Utilities for treatment-related adverse events in type 2 diabetes.
Journal of Medical Economics (2015)
Analysis of primary and secondary APR-DRG codes of an ischemic stroke admission.
Value Health (2015)
​​
​
Investigating the relationship between Severity of Illness and the modified Rankin Scale in ischemic stroke patients with response mapping.
Value Health (2015)
​
​
Time savings with once-monthly C.E.R.A.: a time and motion study conducted in 13 haemodialysis centres in Italy.
Blood Purif (2015)
Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (DR-CLL).
Br J Haematol (2015)
Place of residence and employment status after stroke.
Value Health (2014)
Quality of Life Decrements after Stroke.
Value Health (2014)
Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales (2014)
​​
​
Time and motion studies: opportunities and challenges.
PharmaPhorum (2014)
​
​​
Time savings associated with C.E.R.A. once monthly: a time-and-motion study in haemodialysis centres in five European countries.
J Med Econ (2013)
A budget impact model for paclitaxel-eluting stent in femoropopliteal disease in France.
Cardiovasc Intervent Radiol (2013)
​
​
Investigating Incoherence Gives Insight: the case of anti-platelet therapy for stroke prevention.
J Clin Epidemiol (2012)
Patient Preferences for First-Line Oral Treatment for Mild-to-Moderate Ulcerative Colitis: A Discrete-Choice Experiment.
Patient (2012)
Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany.
Eur J Health Econ (2012)
Quantifying efficiency in healthcare: timing is everything.
Evidence Matters (2012)
​
Cost of hospitalization for cerebrovascular disorders in Belgium.
Acta Neurol Belg (2011)
Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences.
Int J Technol Assess Health Care (2011)
Eliciting health state utilities from the general public for severe chronic pain.
Eur J Health Econ (2010)
​​
​
Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
J Affect Disord (2010)​​​
​​
Cost-effectiveness of warfarin: Trial versus ‘real-life’ stroke prevention in atrial fibrillation.
Am Heart J (2009)
​
​
Time and motion studies: opportunities and challenges.
Evidence Matters (2009)
Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
Med Mal Infect (2009)
Cost-effectiveness of linezolid versus vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
Infection (2009)
Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.
Eur J Health Econ (2009)
​
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Prostate Cancer Prostatic Dis. 11(2):153-9. (2008)
Preferences and utilities for the symptoms of moderate to severe allergic asthma.
Eur J Health Econ. 9(3):275-84 (2008)
​
Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Hemodial Int (2008)
Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A.
Blood Purif (2008)
​
The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
Curr Med Res Opin (2006)
​
Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura.
Pharmacoeconomics-Spanish Res Artic (2007)
​
Health state utilities for metastatic breast cancer.
Br J Cancer (2006)
Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma.
Ann Allergy Asthma Immunol (2006)
​​
​​
Evaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries.
Health Qual Life Outcomes (2006)
​
​
Cost-effectiveness of oral ibandronate compared with intravenous zoledronic acid or intravenous generic pamidronate in breast cancer patients with metastatic bone disease undergoing intravenous chemotherapy.
Support Care Cancer (2005)
Cost-effectiveness of oral ibandronate versus intravenous zoledronic acid or intravenous pamidronate for breast cancer and bone metastases patients receiving oral hormonal therapy in the UK.
Clin Ther (2005)
​
​
The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer.
Med Decis Making (2004)
​​
Hepatitis B management costs in France, Italy, Spain, and the United Kingdom.
J Clin Gastroenterol (2004)
One-year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial.
Heart (2004)
​
​
Continuous retrograde blood cardioplegia is associated with lower hospital mortality after heart valve surgery.
J Thorac Cardiovasc Surg (2003)
​
​
Selecting unit costs for economic analyses: some conceptual and practical issues (discussion paper).
HESG (2003)
De toekomst geplandt: bedrijfsopvolging bij boeren en tuinders.
Leuven: Cera Holding (2000)
